Teva Pharmaceuticals

Teva Pharmaceutical to pay $519 mn to settle US bribery charges

23 Dec 2016

Teva Pharmaceuticals and Mylan accused of brazen price fixing

16 Dec 2016

Aurobindo Pharma to buy some commercial products from Teva

26 Nov 2016

Intas to buy Teva's UK, Ireland generics business for Rs5,083 cr

06 Oct 2016

Teva patent on multiple sclerosis drug invalidated

02 Sep 2016

Aurobindo, Intas in race for Teva's Irish generics business

29 Aug 2016

Mylan wins patent battle over sclerosis drug Copaxone

26 Aug 2016

Allergan to sell US distribution unit Anda to Teva for $500 mn

04 Aug 2016

The sale comes just a day after Teva completed its $40.5-billion acquisition of Allergan’s generic unit, following US regulatory approval a week ago

US antitrust regulator approves Teva-Allergan $40.5 bn generic deal

28 Jul 2016

Teva to sell US generic products to Australia's Mayne Pharma for $652 mn

28 Jun 2016

Teva readies to divest $2 bn in assets to win US regulatory approval for Allergan

06 May 2016

European regulator approves Teva’s $40.5-bn Allergan drug unit deal with conditions

11 Mar 2016

The European Commission yesterday approved Teva Pharmaceutical Industries' $40.5-billion acquisition of the generics drug unit of Allergan on condition that it divests some Allergan products in the UK and Ireland

Teva to buy Mexican drugmaker Rimsa for $2.3 bn

03 Oct 2015

With this acquisition, Teva will become a leading pharmaceutical company in Mexico, the second-largest market in Latin America and one of the top five emerging markets globally

IBM Watson Health, Teva Pharma tie up for Cloud solutions

12 Sep 2015

Teva in $40.5-bn pact to buy Allergan's generics, ends Mylan bid

27 Jul 2015

Post-merger, Allergan will have one of the broadest product portfolios and strongest pipelines in the generics industry

Teva in talks to buy Allergan's generic-drug unit for $45 bn: report

27 Jul 2015

A deal with Allergan would indicate that Teva could be considering abandoning its plan to buy Mylan NV after the Netherlands-based company rejected its $40-billion takeover offer

Teva plans to raise bid for rival drugmaker Mylan to $42 bn

07 Jul 2015

Teva and Mylan's product offerings are highly complementary and, together, would create the broadest portfolio in the global pharmaceuticals industry, with a combined pipeline of over 400 applications for new drugs

Teva pressures takeover target Mylan with 1.8% stake buy

03 Jun 2015

Analysts expect Teva to make a sweetened formal bid for Mylan after raising its stake to the 4.6 per cent threshold, because once it tables a formal bid, it cannot buy Mylan shares from the market

Teva settles US antitrust charges for $1.2 bn

29 May 2015

The world’s biggest generic drug maker Israel’s Teva Pharmaceutical Industries has agreed to settle US antitrust charges for illegally blocking competition to its blockbuster sleep-disorder drug Provigil

Teva Pharmaceutical offers to buy Mylan NV for $40 bn

22 Apr 2015

A successful Teva-Mylan merger would be the largest in the pharmaceutical industry this year, which has seen acquisitions taking place at a frenzied pace

Teva Pharmaceutical to buy US neurology drug firm Auspex $3.5 bn

31 Mar 2015

Auspex is a biopharmaceutical company specialising in applying deuterium chemistry to known molecules to create novel therapies with improved safety and efficacy profiles

US Supreme Court turns down Teva's bid to block Mylan's generic Copaxone

19 Apr 2014

Ranbaxy, Teva to pay $15,000 each to settle US anti-trust case

20 Feb 2014

Teva Pharmaceutical to cut 5,000 jobs, save $2 bn annually

11 Oct 2013

Teva, Sun Pharma to pay Pfizer $2.15 bn to settle patent suit

12 Jun 2013

Teva, the world’s largest generic drug firm, will pay $1.6 billion of the settlement amount while Sun Pharmaceuticals will pay the remaining $550 million

View details about the software product Informachine News Trackers